Wednesday, October 29, 2025 9:21:35 AM
Vivos' strengthened strategic partnership with Exubrion Therapeutics as of 29 October 2025 that includes licensing coordination and shared clinic relationships means Vivos' IsoPet will now be offered in at least 65+ Exubrion Therapeutics' veterinary clinics across the US IN ADDITION TO the 15 total IsoPet Treatement Centers and GROWING.
Capital Veterinary Specialists in Tallahassee, FL joining the IsoPet network was announced on 20 August 2025.
"Q1 [2025] was record breaking and Q2 [2025] is on track to beat those records!" - Vivos on IsoPet Treatments, 7 May 2025.
14 IsoPet treatments scheduled as of 15 September 2025.
Kindred Biosciences was acquired by Elanco Animal Health in 2021 at $9.25 per share.
--
Two separate regulatory approvals (FDA-US and DCGI-India) in relatively quick succession is possible at any time!
GO VIVOS-US GO!!
GO VIVOS-INDIA GO!!
GO VIVOS-ISOPET GO!!
Capital Veterinary Specialists in Tallahassee, FL joining the IsoPet network was announced on 20 August 2025.
"Q1 [2025] was record breaking and Q2 [2025] is on track to beat those records!" - Vivos on IsoPet Treatments, 7 May 2025.
14 IsoPet treatments scheduled as of 15 September 2025.
Kindred Biosciences was acquired by Elanco Animal Health in 2021 at $9.25 per share.
--
Two separate regulatory approvals (FDA-US and DCGI-India) in relatively quick succession is possible at any time!
GO VIVOS-US GO!!
GO VIVOS-INDIA GO!!
GO VIVOS-ISOPET GO!!
Bullish
Recent RDGL News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:45:22 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:44:48 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/06/2026 05:15:04 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 03/04/2026 04:48:52 PM
- Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ • GlobeNewswire Inc. • 02/10/2026 01:30:00 PM
- Vivos Inc Updates Human Therapy Progress in India • GlobeNewswire Inc. • 02/03/2026 01:30:00 PM
- Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals • GlobeNewswire Inc. • 01/28/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2026 04:06:21 PM
- Vivos Inc Summarizes Progress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 05:56:08 PM
- Vivos Inc Summarzes Preogress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 09:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 12:34:42 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:08:03 AM
- Vivos Inc. Issues Shareholder Update Letter • GlobeNewswire Inc. • 11/06/2025 01:30:00 PM
- Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics • GlobeNewswire Inc. • 10/29/2025 12:30:00 PM
- Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel® • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 05:46:00 PM
- Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:01:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 07:32:46 PM
